Newron Pharmaceuticals S.p.A. (LON:0QOI)

Market Cap	132.91M
Revenue (ttm)	42.50M
Net Income (ttm)	13.10M
Shares Out	n/a
EPS (ttm)	0.64
PE Ratio	10.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33
Average Volume	2,224
Open	6.61
Previous Close	6.45
Day's Range	6.57 - 6.61
52-Week Range	4.12 - 10.40
Beta	0.94
RSI	45.87
Earnings Date	Apr 1, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the discovery and development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the trea...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QOI

Financial Performance

Financial numbers in EUR